Life Science & Biotech Blog Posts

Doctors' drug money

July 10, 2014
Comments(0)
Indiana physicians and research organizations reaped more than $25 million in payments from 15 pharmaceutical firms in 2012, according to the most recent data made available by the not-for-profit group ProPublica. Lilly was the biggest spender and the IU medical school was the biggest recipient.
More

A silver lining for Endocyte

May 2, 2014
Comments(0)
The news this morning couldn’t have been worse for Endocyte Inc. But if it had to come, the timing couldn’t have been better--because it allowed Endocyte to raise a pile of cash to spend on the other drugs in its pipeline.
More

Lilly shares hit all-time high for the John Lechleiter era

April 7, 2014
Comments(2)
Court win last week in a patent challenge to lung cancer drug Alimta pushed Lilly shares higher than they've ever been since April 2007. Since then, the company’s pipeline has produced more misfires than the villains in a James Bond movie
More

Life sciences jobs pack 2-for-1 punch

February 24, 2014
Comments(2)
While life sciences companies don’t rack up huge jobs numbers, their relatively high pay means that every job they create is worth two in the rest of the private sector.
More

Health care has priced itself out of its own market

November 18, 2013
Comments(11)
It’s no secret the growth of the U.S. economy slowed in the 2000s after the go-go decade preceding it. But the U.S. health care system—hospitals, doctors, drug companies, device makers and health insurers—apparently didn’t get that memo.
More

BioCrossroads drops dreams for hospital innovation

August 15, 2013
Comments(7)
In this age of austerity, there's almost no chance of Indianapolis hospitals creating a Cleveland Clinic-like hub of innovation.
More

A dose of light reading

August 9, 2013
Comments(2)
Starting with this post, I’m going to periodically give you a peek at my reading list. I’ll highlight reports and reportage that I have found either helpful or provocative. I hope you do, too.
More

Me-too diabetes drugs look good enough for Lilly

June 26, 2013
Comments(2)
Eli Lilly and Co. is more than 15 years late to the game in the world of diabetes drugs. And it isn’t bringing much that doctors and patients haven’t already seen. Still, that might be good enough to make a few billion a year.
More

IT revolution coming to local health care

June 19, 2013
Comments(7)
Local providers will increasingly look for help from IT firms like Indigo Biosystems Inc. and VoCare Inc. as part of a coming wave of health IT innovation that is likely to mirror the IT revolution that began 30 years ago.
More

ADVERTISEMENT
Sponsored by
ADVERTISEMENT
ADVERTISEMENT